Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in advanced ISS stages and select genetic subgroups.
Duct-to-Mucosa versus Other Pancreaticojejunostomy Techniques for Preventing Postoperative Pancreatic Fistula: Updated Evidence and Clinical Insights

Duct-to-Mucosa versus Other Pancreaticojejunostomy Techniques for Preventing Postoperative Pancreatic Fistula: Updated Evidence and Clinical Insights

This Cochrane review update evaluates duct-to-mucosa pancreaticojejunostomy compared to other anastomotic techniques following pancreaticoduodenectomy for preventing postoperative pancreatic fistula, finding very low-certainty evidence and no clear superiority of any method.